Drug firm Lupin Ltd. on Monday said its board has approved the transfer of its API R&D division to a wholly owned subsidiary on a slump sale basis.
The company's board has also approved modification to an earlier slump sale transaction by including an additional brand as part of the transfer of OTC business to LUPINLIFE Consumer Healthcare Ltd., on a going concern basis, the drug maker said in a regulatory filing.
ADVERTISEMENT
The company had intimated on Feb. 12 this year regarding the board's approval for the transfer of the OTC Consumer Healthcare Business to a new wholly owned subsidiary.
The company has incorporated LUPINLIFE Consumer Healthcare, a wholly owned subsidiary for the purpose.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU
SEBI Penalises Reliance Securities For Cybersecurity, Stock Broker Rules Violations
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
Labour Reforms: Gratuity Eligibility Reduced From Five Years To One
Paytm To Consolidate Online, Offline Business Under Payments Arm
POPULAR
1
Indian Co-Workers 'Idiots': Campbell's Puts Executive On Leave After Alleged Racist Rant
2
AI Again? Deloitte Draws Flak For $1.6-Million Canadian Healthcare Report, Weeks After Row In Australia
3
UK Budget: Higher Taxes To More Welfare — Five Key Takeaways
4
Hong Kong Tower Fire Kills At Least 36, With 279 People Missing
5